Categories Earnings, Health Care

AMAG Pharmaceuticals (AMAG) Q4 2019 Earnings Snapshot

— AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019 vs. $0.36 per share loss expected.

— During the fourth quarter, the company recorded impairment charges of $155 million.

Earnings Update by AlphaStreet

— Revenue increased to $89.7 million from $88.1 million last year vs. $88.39 million expected.

— For fiscal 2020, AMAG expects revenue to be between $230 million and $280 million. Non-GAAP adjusted EBITDA is expected to be in the range of $20 million to $50 million.

— 2020 key priorities include completing CEO transition, divest Intrarosa and Vyleesi, drive continued Feraheme growth and work with the FDA to maintain patient access to Makena.

— AMAG also announced today that its Chief Medical Officer Julie Krop will be leaving the company with effect from March 31, 2020. The Board has initiated the search for a permanent CMO.

— AMAG stock had retreated 24% in the past three months and 45% from this time last year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Infographic: Key highlights from Campbell Soup Company’s (CPB) Q1 2023 earnings results

Campbell Soup Company (NYSE: CPB) reported first quarter 2023 earnings results today. Net sales increased 15% year-over-year to $2.57 billion. Organic sales growth was 15%. Net earnings attributable to Campbell Soup

Cancer drug maker Felicitex prepares for IPO. Here’s all you need to know

Fewer companies filed for initial public offering this year, compared to 2021 when the market witnessed a record number of IPOs. With only a few weeks left for the year

Chipotle Mexican Grill (CMG): A few points to keep in mind if you have an eye on this restaurant chain

Shares of Chipotle Mexican Grill Inc. (NYSE: CMG) were down 3% on Tuesday. The stock has dropped 13% year-to-date but there is still a positive sentiment in general about its

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top